Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey

被引：23

作者：

Senol, G

Erbaycu, A

Özsöz, A

机构：

[1] Izmir Chest Dis & Surg Res Hosp, Dept Microbiol, TR-35110 Izmir, Turkey

[2] Izmir Chest Dis & Surg Res Hosp, Dept Chest Dis & TB, TR-35110 Izmir, Turkey

来源：

JOURNAL OF CHEMOTHERAPY | 2005年 / 17卷 / 04期

关键词：

tuberculosis; rifampicin; rifabutin; drug resistance;

D O I：

10.1179/joc.2005.17.4.380

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Rifabutin is a spiro-piperidyl-rifamycin derived from rifamycin-S. This study was planned to determine the minimal inhibitory concentrations (MICs) of rifabutin and rifampicin against Mycobacterium tuberculosis strains and to investigate cross resistance between two drugs. The agar dilution method was performed for detection of MICs of rifabutin and rifampicin for 112 M. tuberculosis strains obtained from patients. with active pulmonary tuberculosis. Cross resistance between rifampicin and rifabutin was detected in 73.1%. Rifabutin MICs for rifampicin resistant strains were three- to four-fold higher than rifabutin-susceptible and/or -resistant strains' MIC values for rifampicin. Despite having 73% cross-resistance with rifampicin in M. tuberculosis isolates, it was concluded that rifabutin might be a valid component of combination therapy in rifampicinresistant tuberculosis cases when the isolate is tested and detected susceptible to rifabutin.

引用

页码：380 / 384

页数：5

共 33 条

[1]

Bergmann JS, 1998, INT J TUBERC LUNG D, V2, P621

[2]

In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations [J].

Cavusoglu, C ;

Karaca-Derici, Y ;

Bilgic, A .

CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (07) :662-665

[3]

Chien HP, 2000, J FORMOS MED ASSOC, V99, P408

[4]

deCian W, 1995, SCAND J INFECT DIS, P22

[5]

DELLABRUNA C, 1994, J ANTIMICROB CHEMOTH, V34, P184

[6]

INVITRO ACTIVITY OF NEW RIFAMYCINS AGAINST RIFAMPICIN-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AND MAIS-COMPLEX MYCOBACTERIA [J].

DICKINSON, JM ;

MITCHISON, DA .

TUBERCLE, 1987, 68 (03) :177-182

[7]

ERKAN L, 2000, J RESP DIS, V11, P396

[8]

FARR BM, 1995, PRINCIPLES PRACTICE, P318

[9]

THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY [J].

FRIEDEN, TR ;

STERLING, T ;

PABLOSMENDEZ, A ;

KILBURN, JO ;

CAUTHEN, GM ;

DOOLEY, SW .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) :521-526

[10]

RIFABUTIN FOR THE TREATMENT OF NEWLY-DIAGNOSED PULMONARY TUBERCULOSIS - A MULTINATIONAL, RANDOMIZED, COMPARATIVE-STUDY VERSUS RIFAMPICIN [J].

GONZALEZMONTANER, LJ ;

NATAL, S ;

YONGCHAIYUD, P ;

OLLIARO, P ;

ABBATE, E ;

MOSCA, C ;

CASADO, G ;

DILONARDO, M ;

GERHART, G ;

BETJEL, I ;

FERREIRALIMA, S ;

NARINHO, AP ;

LOPEZ, R ;

SOUZA, RD ;

CARLOSMOREIRA, A ;

SANTANA, A ;

CRUZ, A ;

MAGAHAES, M ;

MARINHO, A ;

CAVABARRACARDOSO, N ;

BRANAOMONTERO, R ;

PRIJANONDA, B ;

NUCHPRAYOON, C ;

PUNNOTOK, J ;

CHAKORN, T ;

CARPENTIERI, M ;

DOLFI, L ;

MANIERO, A .

TUBERCLE AND LUNG DISEASE, 1994, 75 (05) :341-347

← 1 2 3 4 →